Holen Sie sich die Stockscreener-App
50.39
6.51%
3.08
Handel nachbörslich:
50.33
-0.06
-0.12%
Schlusskurs vom Vortag:
$47.31
Offen:
$47.78
24-Stunden-Volumen:
386.29K
Relative Volume:
1.48
Marktkapitalisierung:
$2.35B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-61.94
EPS:
-0.8135
Netto-Cashflow:
-
1W Leistung:
+2.02%
1M Leistung:
+55.67%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$45.80
$50.75
1-Wochen-Bereich:
$43.05
$50.77
52-Wochen-Spanne:
$23.00
$52.15
Hemab Therapeutics Holdings Inc Stock (COAG) Company Profile
Firmenname
Hemab Therapeutics Holdings Inc
Sektor
Branche
Telefon
45 2138 7627
Adresse
101 MAIN STREET, CAMBRIDGE
Compare COAG vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COAG
Hemab Therapeutics Holdings Inc
|
50.39 | 2.21B | 0 | 0 | 0 | -0.8135 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Hemab Therapeutics Holdings Inc Aktie (COAG) Neueste Nachrichten
Hemab Therapeutics Holdings Ord Shs (Proposed) - TradingKey
Hemab Therapeutics Holdings, Inc. Revenue Breakdown – NASDAQ:COAG - TradingView
Ra Capital Nexus Fund Iv, L.p. Net Worth (2026) - GuruFocus
Mads Nikolaj Behrndt Eriksen Net Worth (2026) - GuruFocus
Biotech IPO gains crush numerous AI listings - PressReader
Biotech IPO gains crush AI listings with standout 55% return - The Edge Singapore
Ananthram Sreenivasa Murthy Net Worth (2026) - GuruFocus
SpaceX Stock Closes At Fresh Low After Seven Straight Days Of Losses - Yahoo Finance
Ai Den Mab Llc Net Worth (2026) - GuruFocus
The Robot Maker's Paradox - Yahoo Finance
Hemab Therapeutics (NASDAQ:COAG) Hits New 12-Month HighWhat's Next? - MarketBeat
Culpeo Minerals expands Chile landholding by 45% with new licences - Yahoo Finance
After Plunging 32.2% in 4 Weeks, Here's Why the Trend Might Reverse for D-WAVE QUANTUM (QBTS) - Yahoo Finance
Insight Global Opens New Seattle Hub to Support Next Phase of Growth Across the Pacific Northwest - Yahoo Finance
DiamondRock Hospitality Company (DRH) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
IREN stock jumps as AI cloud contract wins lift annual revenue target - Yahoo Finance
Why this venture capitalist is bullish on Anthropic's IPO — not OpenAI's - Yahoo Finance
Plug Power vs. FuelCell: Both Are Hot in 2026, but Only One Is Worth Buying Now - Yahoo Finance
QScreen AI Deepens US Institutional Pipeline as Screening Platform Adds Escalation-Based Review Capability - Yahoo Finance
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Why Is Lucid (LCID) Stock Rocketing Higher Today - Yahoo Finance
Sellas Life (SLS) Climbs 12% Ahead of ‘Potentially Company-Defining’ Clinical Trial Result - Yahoo Finance
Hemab Therapeutics (NASDAQ:COAG) Shares Up 5.5%Here's What Happened - MarketBeat
WESTSHORE TERMINALS ANNOUNCES AGREEMENT RENEWAL WITH EVR OPERATIONS LIMITED - Yahoo Finance
Cracker Barrel (CBRL): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Wall Street traders can soon pay for early looks at Truth Social posts - Yahoo Finance
Hemab Therapeutics Holdings, Inc. Common Stock (NASDAQ: COAG) Stock Price, News & Analysis - Kalkine
Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Hemab Therapeutics (NASDAQ:COAG) Trading Down 3.8%Should You Sell? - MarketBeat
Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN) - Yahoo Finance
FY2027 Earnings Estimate for COAG Issued By HC Wainwright - MarketBeat
Hemab Therapeutics' Sutacimig Continues to Support Durable Bleed Reduction, Wedbush Says - Moomoo
Why Is ASML Stock Jumping Over 5% Premarket Today? - Yahoo Finance
Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Analysts Are Bullish on Top NA Stocks: HawkEye 360, Inc. (HAWK), SpaceX (SPCX) - The Globe and Mail
Hemab Therapeutics reports positive Phase 2 sutacimig data - grafa.com
Corning Earnings Preview: What to Expect - Yahoo Finance
Hemab Therapeutics: Strong HMB-002 Data Drive Higher Probability of Success and Lift Price Target from $36 to $46 with Buy Rating - TipRanks
Hemab Advances Bleeding Disorder Pipeline - Sahm
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress - The Manila Times
Hemab Therapeutics Presents Sustained Sutacimig Bleed Reduction Data and Preclinical Factor VII Deficiency Results at ISTH 2026 - Quiver Quantitative
Hemab GT study finds 72% of patients 40+ still bleed weekly - Stock Titan
H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $52 - Moomoo
COAG Maintained by Jefferies -- Price Target Raised to $47 - GuruFocus
Jefferies Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $47 - Moomoo
Hemab Therapeutics' HMB-002 Well Suited for Type 1 Von Willebrand Disease, Wedbush Says - Moomoo
Hemab Therapeutics Hldgs Price Target Raised to $55.00/Share From $42.00 by Wedbush - Moomoo
Hemab Therapeutics (NASDAQ:COAG) Hits New 52-Week High on Analyst Upgrade - MarketBeat
COAG Maintains Rating by Wedbush -- Price Target Raised to $55 - GuruFocus
Hemab Therapeutics (COAG) Registration filing Summary - Quartr
Finanzdaten der Hemab Therapeutics Holdings Inc-Aktie (COAG)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):